US 12049628
Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
granted A61PA61P25/00A61P25/02
Quick answer
US patent 12049628 (Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases) held by Alnylam Pharmaceuticals, Inc. expires Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Jul 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 44
- CPC classes
- A61P, A61P25/00, A61P25/02, A61P25/28, A61P43/00